title: Totally implantable central venous access devices in children with hemato-oncologic malignancies: evaluation of complications and comparison of incidence of febrile episodes with similar patients without central venous access devices.
abstract: The incidence of mechanical and infectious complications of totally implantable central venous access devices (TIDs) must be related to underlying disease, intensity of the chemotherapy, and frequency of manipulations. Records of the patients hospitalized from January 2002 to May 2005 were evaluated. Patients with TIDs were matched with patients without TIDs having the same malignancy and the same anti-neoplastic chemotherapy. Catheter-related complications were documented and corresponding phases of the chemotherapy in matched pairs were compared with regard to infections. TIDs were inserted in 31 patients with a median age of 4.3 years (22 acute leukemia, 1 NHL, and 8 solid tumors). Total number of catheter days was 5268, with a median catheter life of 174 days (range 9-493 days). Nine catheters (29%) were removed due to mechanical and infectious complications. There was 13 catheter-related infections with a rate of 2.46/1000 catheter days. Total number of mechanical complications was 5 and overall rate of complications was 3.41/1000 catheter days. The rate of febrile episodes was 54 and 41 in the TID and no TID group, respectively (p: .11). Duration of neutropenia was 9.6 and 7.4 days and duration of fever per febrile attack was 5.6 and 4.4 days in the TID and no TID group, respectively (p: .047 and .56). Although most of the patients in this study had hematological malignancy and required frequent manipulation, the results were similar to those in developed countries. TIDs are essential for management of chemotherapy in pediatric malignancies with acceptable complications.
authors.affiliation: Department of Pediatric Hematology, Kocaeli University, Kocaeli, Turkey. nazan_sarper@hotmail.com
authors.forename: Nazan
authors.initials: N
authors.lastname: Sarper
authors.forename: Emine
authors.initials: E
authors.lastname: Zengin
authors.forename: Funda
authors.initials: F
authors.lastname: Corapçioglu
authors.forename: Melih
authors.initials: M
authors.lastname: Tugay
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002675:Child, Preschool; D004868:Equipment Failure; D005334:Fever / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy*; D006801:Humans; D009503:Neutropenia / Q000209:etiology; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents